Significance of neutrophil to lymphocyte ratio in prostate lesions with special reference to prostate cancer

Sushma Shankar; Argha Baruah; C.S.B.R. Prasad

Significance of neutrophil to lymphocyte ratio in prostate lesions with special reference to prostate cancer

Original Article

Author Details : Sushma Shankar, Argha Baruah, C.S.B.R. Prasad

Volume : 3, Issue : 2, Year : 2018

Article Page : 96-100

https://doi.org/10.18231/2581-3706.2018.0021

Suggest article by email

Get Permission

Abstract

Aim: To study the significance of neutrophil- lymphocyte ratio (N:L ratio) in prostate lesions, especially in cases of prostate cancer (PCa).
Materials and Methods: Fifty cases of PCa and fifty cases of benign prostatic hyperplasia (BPH), diagnosed on transurethral resection of prostate biopsies were included in the study. Hematological parameters were recorded, N:L ratio was calculated in all cases and values were compared between BPH and PCa, further association between pathological characters of PCa and N:L ratio values was studied.
Results: In the present study, we found a statistically significant high N:L ratio in PCa cases as compared with BPH cases (p=0.008). We also found a significant difference in the PSA values (p<0.001) and ESR (0.001) between the benign and malignant groups. However hemoglobin, platelet counts and total leucocyte counts did not show a significant difference between the two groups. Sub group analysis failed to show an association between prognostic markers like PSA (p=0.838), gleason score (p=0.161), T (p=0.052) N (p=0.225) M (p=0.529) stage and N:L ratio.
Conclusion: In this study, significant difference in N:L ratio was noted between BPH and PCa, but no association could be demonstrated between N:L ratio and prognostic markers in PCa. Hence N:L ratio cannot be used as a prognostic marker in PCa.

Keywords: Prostate cancer (PCa), N:L ratio.

How to cite : Shankar S, Baruah A, Prasad C, Significance of neutrophil to lymphocyte ratio in prostate lesions with special reference to prostate cancer. IP J Diagn Pathol Oncol 2018;3(2):96-100

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.